Huaping Tang is currently Senior Director, Immunoassay Bioanalysis and Biomarker in the Department of Bioanalysis, Immunogenicity, and Biomarker (BIB) at GlaxoSmithKline. His group is responsible for immunoassay-based analysis of drugs and soluble biomarkers to support preclinical and clinical development. Before joining GSK, Huaping was in the Global Bioanalytical (BA) Group at Merck for over five years, where he focused on regulated PK, immunogenicity, and target engagement biomarker assays for biologics and vaccines, responsible for development, validation, and execution of bioanalytical assays to support regulated preclinical and clinical studies. Prior to joining Merck, Huaping worked for Bristol-Myers Squibb, where he led a group specializing in high throughput phenotypic assays for lead discovery and optimization, and a high-throughput miniaturized biomarker screening platform to support translational biomarker discovery. Huaping received his PhD from Yale University and obtained his post-doctoral training at the Novartis Institutes for Biomedical Research in oncology targeted therapy.